Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

Autor: Diane Tribble, Evan A. Stein, Cara East, Wai Chin, Robert Dufour, Joanne M. Donovan, Daniel Gaudet, Mary P. McGowan, Claude Gagné

Publikováno v: Circulation. 126:2283-2292

Background— Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail to achieve low-density lipopro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f39d93379a296e37de99bc0802200cd9
https://doi.org/10.1161/circulationaha.112.104125

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

Autor: Diane Tribble, Mark K. Wedel, John J.P. Kastelein, Fatima Akdim, Brenda F. Baker, JoAnn Flaim, Rosie Z. Yu, Rainard Fuhr, Richard S. Geary, John Su

Publikováno v: European heart journal, 32(21), 2650-2659. Oxford University Press

Aims Mipomersen, an apolipoprotein (apo) B synthesis inhibitor, has been shown to produce potent reductions in apoB and LDL-cholesterol levels in animal models as well as healthy human volunteers. A randomized, double-blind, placebo-controlled, dose-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a30abfe1b416e8a71b67eaaa5206fe4b
https://doi.org/10.1093/eurheartj/ehr148

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

Autor: Mark K. Wedel, Mieke D. Trip, John Su, Erik S.G. Stroes, J. Wouter Jukema, Eric J.G. Sijbrands, Diane Tribble, Brenda F. Baker, John J.P. Kastelein, Rosie Z. Yu, JoAnn Flaim, Fatima Akdim

Publikováno v: Journal of the American College of Cardiology, 55(15), 1611-1618. Elsevier Inc.
Journal of the American College of Cardiology, 55(15), 1611-1618
Journal of the American College of Cardiology, 55(15), 1611-1618. Elsevier USA

Objectives The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy. Background Mipomersen is an apolipoprotein (apo) B synthesis inhibitor that has demonstrated signifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e754c064d779a828122d09d679769d0

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men

Autor: Aditi Sapre, Klaus von Bergmann, Dieter Lütjohann, Patrice H. Gibbons, Thomas Musliner, William Taggart, Thomas Sudhop, Michael Reber, Diane Tribble

Publikováno v: Journal of Lipid Research, Vol 50, Iss 10, Pp 2117-2123 (2009)

This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5228063e1004c80f47699d4ac91a015
https://doi.org/10.1194/jlr.p900004-jlr200

Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques

Autor: Thomas Musliner, Diane Tribble, Aditi Sapre, Robert Reyes, Amy O. Johnson-Levonas, Leiv Ose

Publikováno v: Clinical Therapeutics. 29:2419-2432

Background: Cholesterol-rich lipoproteins, including low-density lipoprotein cholesterol (LDL-C), intermediate-density lipoprotein cholesterol (IDL-C), and very-low-density lipoprotein cholesterol (VLDL-C), are known to promote atherosclerosis. Ezeti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e3cb2d94676e41fd701506dc2c2398
https://doi.org/10.1016/j.clinthera.2007.10.004